| Project/Area Number |
15591494
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
IKEDA Norihiko Tokyo Medical University, Medicine, Assistant Professor, 医学部, 講師 (70246205)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HIRANO Takashi Tokyo Medical University, Medicine, Assistant Professor, 医学部, 講師 (30238381)
HONDA Hidetoshi Tokyo Medical University, Medicine, Stuff, 医学部, 助手 (70246297)
KATO Harubumi Tokyo Medical University, Medicine, Professor, 医学部, 教授 (20074768)
本多 英俊 東京医科大学, 医学部, 助手 (60349503)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 2004: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2003: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | lung cancer / biomarker / p16 / methylation / cytometry / early cancer / screening / P16 / 癌遺伝子 / 癌抑制遺伝子 / 肺癌検診 |
|---|
| Research Abstract |
Our biomarker research was classified into two projects as described below.
(1)Detection of aberrant p16 promoter methylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients using real-time PCR.
(Materials and Methods) Serum samples were obtained from 95 patients with non-small cell lung cancer and 32 normal controls and evaluated the quantity of p16 promoter methylation using real-time PCR.
(Results) Aberrant p16 promoter methylation of the tumor suppressor gene was detected in 25 of 95 NSCLC patients (mean:18.613±5.090), but only 2 of 32 normal control (mean: 1.258±0.871). There was a statistical difference between non small cell lung cancer patients and normal control (t-test: p<0.003). Sensitivity was 26.3%, specificity, 93.8%, accuracy, 43.3%, and positive predictive value 92.6%, respectively.
(Conclusion) Detection of aberrant p16 promoter hypermethylation in serum using real time PCR appears useful for lung cancer diagnosis and early detection.
(2)Cytometry analysis of normal cells for the evaluation of lung cancer risk
(Material and Methods) Sputum samples were collected from 52 lung cancer cases and 54 controls. Also buccal smears were collected from 69 lung cancer cases and 45 controls. These samples were analyzed by high resolution cytometry and 100 nuclear features were evaluated in each cell.
(Results) Statistical analysis revealed normal cells from cancer group were well distinguished from normal cells from control group by the combination of 10 features. Based on this result, test set program to evaluate the lung cancer risk was created.
Our two projects demonstrated the feasibility of biomarker research using blood, sputum and buccal cells.
|
